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Abstract
Alloimmunization against human platelet antigen (HPA)-1a during pregnancy can 
cause foetal/neonatal alloimmune thrombocytopenia (FNAIT) and severe bleeding 
in the foetus or newborn and likely depends on several factors. HPA-1a alloimmun-
ization is associated with DRB3*01:01, which is associated with several DR-DQ 
haplotypes. However, it is not known to what extent these haplotypes contribute 
to the prevalence of HPA-1a alloimmunization. HPA-1a–alloimmunized women, 
identified in a prospective study, and random donors were typed for selected DRB3, 
DRB4, DRB1, DQA1 and DQB1 alleles to determine allele and DR-DQ haplotype 
frequencies. DRB3*01:01 was carried by 94% HPA-1a–immunized women com-
pared to 27% in the general population. In the first population, the DR3-DQ2 haplo-
type was overrepresented (P < .003). The prevalence of HPA-1a alloimmunization 
was estimated to be about twice as frequent with DR3-DQ2 compared to DR13-DQ6, 
together accounting for about 90% of DRB3*01:01–positive individuals. Further, 
we examined DQB1*02 and DRB4*01:01 alleles for their reported association with 
HPA-1a alloimmunization, in the context of DR-DQ haplotypes. Since  ~  80% of 
DQB1*02 alleles are linked to the DR3-DQ2 haplotype, the association might be 
coincidental. However, the DQB1*02:02–associated DR7-DQ2 haplotype was also 
overrepresented in alloimmunized women, suggesting a role for this allele or haplo-
type in HPA-1a alloimmunization. As DRB4*01:01 is predominantly associated with 
the DR7-DQ2 haplotype in HPA-1a–alloimmunized individuals, the reported associ-
ation with FNAIT may be coincidental. Typing for DR-DQ haplotypes revealed im-
portant genetic associations with HPA-1a alloimmunization not evident from typing 
individual alleles, and the presence of different DRB3-associated DR-DQ haplotypes 
showed different prevalence of HPA-1a alloimmunization.
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1 |  INTRODUCTION
FNAIT is a rare condition that can cause severe complications 
such as intracranial haemorrhage in the foetus or newborn 
due to the transfer of platelet-depleting alloantibodies from 
the mother to the foetus during pregnancy. The most common 
cause of FNAIT is maternal alloantibodies directed against 
HPA-1a on foetal platelets. This fetomaternal incompatibility is 
defined by a leucine/proline polymorphism at residue 33 in in-
tegrin β3.1 About 2% of Caucasian women are homozygous for 
the HPA-1 variant with proline (HPA-1bb). Alloimmunization 
occurs in about 10% of these women,2 and about one third of 
these will give birth to a child with FNAIT. The most severe 
complication is intracranial haemorrhage (ICH), which occurs 
in approximately 1 in 10,000 unselected pregnancies.2 Several 
factors may in theory affect the natural history of FNAIT, as 
reviewed by Sachs and Santoso (2017),3 including the influ-
ence of the maternal HLA class II genotype. The MHC class 
II allele HLA-DRB3*01:01 is strongly associated with HPA-1a 
alloimmunization; more than 90% of immunized women carry 
this MHC allele,4-6 which also shows a dose-dependent asso-
ciation to the severity of HPA-1a immunization.7 This strong 
genetic association suggests that HPA-1a immunization is de-
pendent on T cells restricted by the MHC class II molecule 
encoded by the HLA-DRA/DRB3*01:01 alleles. There is sup-
port for this notion: HPA-1a– but not HPA-1b–derived peptides 
bind this molecule, and the allogeneic residue Leu33 serves to 
anchor the peptide.8,9 Furthermore, HPA-1a–specific CD4+ T 
cell clones have been isolated from alloimmunized women,10-12 
and these T cell clones are restricted by DRA/DRB3*01:01.10 
However, it is possible that there exist additional genetic fac-
tors that predispose for immunization. In that respect, both 
DQB1*02 and DRB4*01 have been shown to be associated 
with FNAIT.1314 However, these alleles and other genetic el-
ements that may influence HPA-1a alloimmunization do not 
segregate entirely independently of each other. Rather, they are 
in linkage disequilibrium with other genes in conserved hap-
lotypes. In this respect, the DRB3*01:01 allele is known to be 
in linkage disequilibrium with several different DR-DQ haplo-
types, and one of these contains a DQB1*02 allele.15,16
In the present study, we aimed to examine the impact of 
DRB3*01:01–associated DR-DQ haplotypes on HPA-1a 
alloimmunization, and to determine the haplotype associ-
ations and relative importance in HPA-1a alloimmuniza-
tion for HLA-DQB1*02:01/*02:02 and HLA-DRB4*01:01 
alleles.
2 |  METHODS
The study was approved by the Regional Committee for 
Medical Research Ethics, North Norway (approval no. P 
REK NORD 66/2005, 2009/1585 and 2012/1917). Blood 
samples were drawn from patients and healthy volunteers 
after written informed consent.
2.1 | Study groups
In total, 167 HPA-1a–immunized women were included in 
the study comprising two different populations: one group of 
HPA-1a–negative women who developed anti-HPA-1a IgG 
antibodies in connection with pregnancies, included from the 
Norwegian prospective FNAIT screening study (1995-2004) 
(prospective screening group, N = 123)4 ( More than 2/3 of 
these immunized women were included from the southern 
part of Norway), and one group of women referred to the 
Norwegian National Unit for Platelet Immunology (NNUPI) 
after giving birth to a child with severe thrombocytopenia 
and clinical signs of bleeding, also producing anti-HPA-1a 
IgG antibodies (retrospective group, N = 44). The criteria for 
inclusion of both subgroups were detectible levels of anti-
HPA-1a antibodies.
The control group was made of 781 healthy random 
blood donors at the University Hospital of North Norway, 
referred to as the general population. No information re-
garding ethnicity was available for neither the random do-
nors nor the immunized women. The Sami population is 
known to differ from the Norwegian population in several 
HLA types.17 However, most individuals were expected to 
be Caucasians in both groups as all donors were recruited 
from the Norwegian population, and not from specific 
Sami areas of Norway. The frequency of DQB1*02 in our 
control population also fits the frequency of DQB1*02 in a 
group of about 8000 Norwegian donors at the bone marrow 
registry (32,6%), lending support to the notion that the con-
trol population in this study reflects the general population 
in Norway.
2.2 | DNA isolation
Cryopreserved genomic DNA was available from about 40% 
of the HPA-1a–alloimmunized women. In addition, DNA 
was isolated from blood samples from the rest of alloimmun-
ized women and all randomly selected donors, using Blood 
Mini Kit (QIAGEN) and eluted in sterile H2O. Short-time 
storage of DNA was carried out at −20ºC whereas −70ºC 
was used for long-time storage.
2.3 | Genotyping
Primer sequences, characteristics and cycling programs are 
listed in supplementary data (Tables S1 and S2). All primers 
were synthesized by Eurogentec (Belgium). All PCR were 
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performed in a total volume of 25µL, using 0.5U HotStarTaq 
(Qiagen) per reaction, and run on a GeneAmp9700 (Applied 
Biosystems). HGH was used as an internal DNA amplifica-
tion control.18 Genomic DNA from IHWG cell lines was 
used as controls for amplification, specificity and enzyme 
digestion: STEINLIN, DUCAF, EMJ, LZL, CEPH-1413, 
HAG, BER, WDV and EK (Table S3).
Restriction cutting of PCR products was performed with 
endonucleases (all from New England Biolabs) according to 
references (Table S2).
The risk of false-positive detection within each genotyp-
ing assay, for example amplification of infrequent alleles by 
group-specific primers, could be evaluated by conferring 
dbMHC (the MHC database) with updated sequences.
2.3.1 | Designation of HLA-DR-
DQ haplotypes
HLA-DR-DQ haplotypes for each donor were designated 
based on known DR-DQ haplotypes in the Norwegian popu-
lation,15,17,19 based on typing of selected DR- and DQ alleles. 
To answer our main questions in this study, alleles known to 
be associated with DRB3*01:01 and DQB1*02 were specifi-
cally typed for (Table 1).
2.3.2 | Detection of DRB3*01:01P
Detection of DRB3*01:01P (http://hla.allel es.org/allel es/p_
groups.html) was performed for all immunized women and 
random donors by PCR using sequence-specific primers 
for DRB3*01:01/*03:01,20 combined with restriction frag-
ment length polymorphism (RFLP) by the enzyme KpnI, 
cutting amplified DRB3*01:01, but not DRB3*03:01. All 
DRB3*01:01–positive random donors (213) and immunized 
women (157) were included for further detection of HLA-DR 
and –DQ alleles.
Because the above-mentioned method of DRB3*01:01 
detection is both time- and resource demanding, we also 
developed a new DRB3*01:01 typing assay. This assay 
was performed for almost all individuals as duplex assay 
for DRB3*01:01 and GAPDH in a TaqMan RQ-PCR 
assay on genomic DNA: 10 to 100 ng DNA was used in 
25 μL reactions, in parallel reactions, with TaqMan Fast 
Universal PCR Master Mix, run on Fast mode (95°C for 
20  seconds followed by 40 cycles of 95°C for 1  second 
and 60°C for 20 seconds) on ABI Prism7900HT (Applied 
Biosystems).
Oligos for HLA-DRB3: HLA-DRB3 primers (1000nM) 
5’- TCTTGGAGCTGCGTAAGTCTGA-3’, 5’-TGTTCCAG 
GACTCGGCGA-3’ and a specific HLA-DRB3*01:01 
probe (150  nM) 5’-6-FAM-TCTPTCCAGGZACCG-BHQ- 
1-3' (P= G-LNA, Z=T-LNA nucleotides). For GAPDH as 
reference, primers (500nM) 5’-CCCCACACACATGCACT 
TACC-3’, 5’-CCTAGTCCCAGGGCTTTGATT-3’ and a 
probe (100nM) 5’-VIC-AAAGAGCTAGGAAGGACAGGC 
AACTTGGC-BHQ-1-3’. Samples from fully HLA typed 
cell lines were used as controls for method development: 2 
copies of DRB3*01:01 (STEINLIN), 1 copy of DRB3*01:01 
(D4BL4 in-house), as well as DRB3*01:01–negative, 
DRB3*02:02/DRB3*03:01–positive samples (DUCAF/
EMJ).
2.3.3 | Detection of DQB1*02 and DQA1*05
Group-specific primers for DQB1*02 and DQA1*05 were 
multiplexed.21,22 The primers for DQA1*05 and DQB1*02 
theoretically amplify all alleles in the two different groups. 
To discriminate between the allele DQB1*02:02 and other 
DQB1*02 alleles, typing for DQB1*02 23 was combined with 
digestion by the restriction endonuclease MscI, cutting only 
the amplified product of DQB1*02:02 in exon 3 of the DQB1 
gene.
2.3.4 | Detection of DRB1*03:01, 
(*11:01/*11:02), *13:01, *13:02, *13:03, 
(*14:01)
Group-specific primers for two groups of alleles were used.24 
Primers for Group-1 amplified DRB1*11:01, *13:02, and 
*13:03. The restriction endonucleases, FokI and SfaNI, were 
Haplotype DRB1 DQA1 DQB1 
Additional DRB 
association
DR3- DQ2 *03:01 *05:01 *02:01 DRB3*01:01
DR13(01)- DQ6 *13:01 *01:03 *06:03 DBR3*01:01
DR13(03)-DQ3 *13:03 *05:01 *03:01 DRB3*01:01
DR7- DQ2 *07:01 *02:01 *02:02 DRB4*01
DR7- DQ3 *07:01 *02:01 *03:03 DRB4*01
All alleles are written in italic. Alleles specifically typed for in this study are in bold.
T A B L E  1  Common HLA alleles and 
HLA DR-DQ haplotypes in the Norwegian 
population, specifically typed for in this 
study. Adapted from Spurkland et al, 
Harbo et a and Lande et al,15,17,19 with 
modifications in DRB1*1331
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used to distinguish between these three DRB1 alleles. Primers for 
Group-2 amplified DRB1*03:01, *11:02, *13:01, and *14:01. 
The restriction endonucleases FokI, SfaNI and KpnI were used 
to distinguish between these alleles. For details, see Table S2.
2.3.5 | Detection of DRB1*07
Detection of DRB1*07 was done by group-specific PCR for 
DRB1*07.25
2.3.6 | Detection of DRB4*01:01
Two sets of primers and restriction endonucleases, for exon 
2 and exon 3, were used. The first group-specific primers 
for DRB4*01 in exon 2 amplify all DRB4*01 alleles except 
DRB4*01:05.26 Samples positive in the first PCR were fur-
ther typed for exon 3, with primers specific for DRB4*01:01, 
-*01:02, -*01:03, -*01:06, -*02:01, and -*03:01.27 The 
restriction endonuclease EaeI cuts DRB4*01:01 and 
DRB4*01:06. Hence, samples with amplified products in 
both reactions and only restricted by the EaeI enzyme could 
be DRB4*01:01 and/or DRB4*01:06 positive.
2.3.7 | Confirmation of haplotypes and 
additional haplotype detection
To support the assigned DRB3*01:01–associated haplotype, 
for each immunized women and each individual in the con-
trol group, based on the results of PCR-RFLP genotyping 
and to uncover the additional haplotype, low-resolution typ-
ing for DRB1 was performed by the Norwegian Bone Marrow 
Registry in Oslo, Norway; donors were typed for HLA-DRB1 
by oligonucleotide probing defining HLA-DR1, DR2, DR3, 
DR4, DR7, DR8, DR9, DR10, DR11, DR12, DR13, DR14 
and DR103 specificities. Due to too low amounts of DNA, 
some donors could not be low-resolution typed or typed for 
DRB4*01:01. However, all individuals included for analysis 
of the DRB3*01:01–associated haplotype were still sufficient 
typed to define the associated haplotype. Donors not typed for 
DRB4*01:01 were excluded from the statistical analysis of 
DRB4*01:01 or its associations. ‘N’ is given for each statisti-
cal analysis.
2.4 | Estimating the prevalence of HPA-1a 
alloimmunization with different DRB3*01:01–
associated haplotypes
The prevalence of alloimmunization was estimated by 
combining data from the Norwegian FNAIT screening 
study with data from the general population (control pop-
ulation in the current study). The number of HPA-1a–
negative women in the screening study who carried the 
various DRB3*01:01–associated DR-DQ haplotypes was 
estimated by applying the population frequencies of these 
haplotypes determined for the general population (con-
trol population in the current study). Patient samples of 
HPA-1a–alloimmunized women from the screening study 
were also examined for these haplotypes. The prevalence 
of HPA-1a alloimmunization was calculated as the per cent 
of HPA-1a–negative women who eventually became allo-
immunized, for each DR-DQ haplotype. Not all HPA-1a–
immunized women were included for HLA typing due to 
lack of DNA. The results from our typing of a proportion 
of immunized women were therefore adjusted to apply to 
the whole population of immunized women. Estimates are 
shown in Figure 1. Statistical analyses could not be used 
for estimated prevalence numbers. In support of the ac-
curacy of these estimates, the binomial test for measured 
frequencies of these haplotypes showed that the HPA-1a–
immunized individuals were significantly different from 
the general population.
2.5 | Genotyping of TNF-308, LTA252 and 
AGER-429 SNPs
TNF −308G>A (rs1800629), LTA 252A>G (rs909253) and 
AGER-429T>C (rs1800625) SNPs were determined with al-
lelic discrimination assays. Primers and probes are listed in 
Table S4.
2.6 | Statistics
To compare allele and haplotype frequencies between two 
groups, the chi-square test was used. Differences between 
groups were considered significant if P < .05. As the number 
of a priori hypotheses was small and related to specific hap-
lotypes, correction for multi-significance was not applied as 
recommended by Perneger TV.28
3 |  RESULTS
3.1 | The DR3-DQ2 haplotype occurs 
at a higher frequency among HPA-1a–
alloimmunized women than would be expected 
by random distribution
To identify the most common DR-DQ haplotypes in 
linkage disequilibrium with the HLA-DRB3*01:01 al-
lele, we first identified DRB3*01:01 positives among 
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F I G U R E  1  The estimated prevalence for HPA-1a alloimmunization is twice as high for women carrying DR3-DQ2 compared to DR13-
DQ6. (A) The prevalence of HPA-1a alloimmunization for groups of women with different DRB3*01:01–associated DR-DQ haplotypes in a 
prospectively selected population was examined by combining data from the Norwegian screening study 4 and DR-DQ haplotype data generated 
in the current study. (B) Each bar represents individuals enrolled in the Norwegian screening study projected to carry one or two DRB3*01:01–
associated DR-DQ haplotypes. The width of each bar represents the proportion of individuals with the indicated DR-DQ haplotype, projected from 
measured frequency of individuals carrying the different DRB3*01:01–associated DR-DQ haplotypes in the general population. The height of each 
bar represents the estimated prevalence of HPA-1a alloimmunization and is based on the actual number of HPA-1a–alloimmunized individuals 
determined to carry the specific haplotype. The overall prevalence of HPA-1a alloimmunization in DRB3*01:01–positive individuals is 36.5%.
The prevalence of immunization with DR3-DQ2 (44.5%) is about twice as high as for DR13-DQ6 (22.9%). The accuracy of these estimates is 
supported from binomial test of statistical significance for measured frequencies of these haplotypes in the HPA-1a–immunized individuals against 
the general population: Frequency of HPA-1a–alloimmunized women with DR3-DQ2 (71,8%, n = 116) against the general population (58.7%): 
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HPA-1a–immunized individuals (n  =  167) (both pro-
spectively and retrospectively selected) and in the gen-
eral population (n  =  781). The same populations were 
also typed for HLA-DQB1*02 and HLA-DRB4*01 alleles 
since these have also been reported to be associated with 
HPA-1a immunization.
As expected, in total, 94% (157) of the HPA-1a–immu-
nized women carried the DRB3*01:01 allele, compared 
to only 27.3% (213) of the general population (P <  .0001; 
Table 2); notably near similar frequency of DRB3*01:01 was 
found in the general population in other countries.29
Almost all immunized women and random donors were 
also typed by the TaqMan assay for detection of DRB3*01:01, 
and the results were in concordance with the old assay for 
typing of DRB3*01:01.
In total, 82.0% of the HPA-1a–immunized women carried 
a DQB1*02 allele, compared to only 31,0% in a random se-
lection of the general population (P < .0001) (Table 2).
Only 10.5% of HPA-1a–immunized women carried the 
DRB4*01:01 allele, not significantly different from 6.9% in a 
random selection of the general population (P = .23) (Table 2).
Next, in a detection regime to identify DRB3*01:01–as-
sociated DR-DQ haplotypes, DRB3*01:01–positive individ-
uals were further genotyped for selected alleles (as outlined 
in ‘Methods’). DRB3*01:01 is known to be associated with 
DRB1*03, DRB1*11, DRB1*12, DRB1*13 and DRB1*14 
alleles.29 However, some of the combinations are very rare 
in Caucasians.29 DR alleles known to be associated with 
DRB3*01:01 were successfully identified in 98.6% of ran-
dom donors, and all but one of the immunized women. For 
the remaining random donors and immunized woman, we 
did not have enough DNA to perform low-resolution typing 
for DRB1; the typing results were therefore uncertain.
A comparison of the DRB3*01:01–associated DR-DQ 
haplotypes (Table  3) showed that there were two dominat-
ing haplotypes, DR3-DQ2 and DR13-DQ6, together ac-
counting for > 90% of the immunized women. Furthermore, 
individuals with DR3-DQ2 were overrepresented among 
HPA-1a–immunized women (80.9%), compared to the gen-
eral population (66.7%; P < .003). In the remaining few per 
cent of immunized women, DRB3*01:01 was associated with 
less frequent haplotypes.
3.2 | DR3-DQ2 is overrepresented in 
both the retrospective and the screening groups
The HPA-1a–alloimmunized women in the study comprised 
of women identified in connection with a prospective screen-
ing study described previously 4 and women referred from the 
Allele
HPA-1a–alloimmunized 
women General population  
DRB3*01:01 94.0a (N = 167) 27.3 (N = 781) P < .0001
DQB1*02 82.0 (N = 167) 31.0 (N = 200) P < .0001
DRB4*01:01 10.5 (N = 153) 6.9 (N = 204) P = .23
Note: Number of individuals typed for the indicated allele in each population.
aPer cent of individuals in each population that typed positive for the indicated allele. 
T A B L E  2  Frequency of individuals 
carrying DRB3*01:01, DQB1*02 
and DRB4*01:01 alleles in HPA-1a–
alloimmunized women and in the general 
Norwegian population
F I G U R E  2  The frequency of the DR3-DQ2 haplotype in the general population and in HPA-1a–immunized women. Both in a population 
of HPA-1a–alloimmunized DRB3*01:01–positive women identified in a prospective screening study,4 ‘Screening population’, and in a 
population consisting of women referred from the clinic following identification of suspected FNAIT cases, ‘Retrospective population’, the per 
cent individuals carrying the DR3-DQ2 haplotype were higher than in a general population of DRB3*01:01–positive individuals (screening: 
difference12.6%, P = .016. Retrospective: difference 18.7%, P = .017). The ‘Retrospective population’ is likely enriched in women who gave 
birth to severely thrombocytopenic neonates compared to the ‘Screening population’, in which roughly a third of affected neonates were severely 
thrombocytopenic
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clinic following a pregnancy where FNAIT was diagnosed. 
Both groups showed overrepresentation of DR3-DQ2, 79.3% 
in the prospective group and 85.4% in the retrospective group 
(Figure 2), compared to 66.7% in the general population (diff 
12,6, P = .016; diff 18,7, P = .017). Population frequencies 
of DRB3*01:01–associated DR-DQ haplotypes in each of 
these groups are shown in Figure S1.
3.3 | More women become HPA-1a 
alloimmunized when DRB3*01:01 is associated 
with the DR3-DQ2 haplotype
Since the proportion of those who have the DR3-DQ2 hap-
lotype is higher in the immunized population in this study 
compared to the control population, we wanted to deter-
mine the prevalence of HPA-1a alloimmunization among 
DRB3*01:01–positive individuals having this or other 
DR-DQ haplotypes, that is the proportion of women with 
different DRB3*01:01–associated DR-DQ haplotypes who 
have become alloimmunized after one or several incompati-
ble pregnancies. In lack of a control group of non-immunized 
HPA-1a–negative women, which would have been our pre-
ferred control group, the prevalence of immunization among 
women with different haplotypes had to be estimated. For 
this estimation, we used data from the Norwegian FNAIT 
screening study, in which more than 100.000 women were 
screened for HPA-1a negativity and HPA-1a alloimmuniza-
tion in connection with pregnancy. Since DR-DQ haplotypes 
were not determined for subjects in the screening study, we 
estimated the proportion of the women carrying the differ-
ent DRB3*01:01–associated DR-DQ haplotypes by apply-
ing the frequency of each of the DRB3*01:01–associated 
DR-DQ haplotypes determined for the control population in 
the current study. The prevalence of alloimmunization was 
then calculated from the number of HPA-1a–alloimmunized 
women with a particular DRB3*01:01–associated DR-DQ 
haplotype (typed in the current study) and the estimated 
number of HPA-1a–negative women in the screening study 
who carried the same haplotype (Figure 1A). The prevalence 
of alloimmunized HPA-1a–negative, DRB3*01:01–positive, 
DR3-DQ2–positive women was 44.5%, that for DR13-DQ6 
haplotype is only 22.9% (Figure 1A,B). Hence, in HPA-1a–
negative DRB3*01:01–positive women, we estimate that 
about twice as many will become HPA-1a–alloimmunized 
during or after one or multiple HPA-1a–incompatible preg-
nancies when the DRB3*01:01 allele is associated with the 
DR3-DQ2 haplotype, compared to those with DR13-DQ6. 
The same approach was used to calculate the prevalence of 
alloimmunized HPA-1a–negative, DRB3*01:01–positive 
women: 36.5%.
3.4 | The DR7-DQ2 haplotype and 
DRB4*01:01 are overrepresented and DR15-
DQ6 is underrepresented in DRB3*01:01–
positive HPA-1a–alloimmunized women
Both haplotypes were successfully determined, by low-
resolution DRB1 typing combined with typing for specific 
alleles, in 197 of 213 (92%) individuals in the DRB3*01:01–
positive general population group and in 139 of 157 (88%) of 
HPA-1a–immunized DRB3*01:01–positive women.
Although all individuals in this study carry the DRB3*01:01 
allele on one or both chromosomes, HLA-DQB1*02 is also 
strongly associated with HPA-1a alloimmunization.13 HLA-
DQB1*02 is present in two different DR-DQ haplotypes. 
The HLA-DQB1*02:01 allele is in linkage disequilibrium 
with DRB3*01:01 in the DR3-DQ2 haplotype, while HLA-
DQB1*02:02 is present in the DR7-DQ2 haplotype, which 
segregates independent of DRB3*01:01. Furthermore, a neg-
ative association with HPA-1a alloimmunization has been 
reported for HLA-DRB1*15:01.30 This allele is present in 
DR15-DQ6, which also segregates independent of HLA-
DRB3*01:01. To determine the relative influence of these two 
DR-DQ haplotypes on HPA-1a alloimmunization, we inde-
pendently typed for DR7-DQ2 and DR15-DQ6 on the second, 
non–DRB3*01:01-associated chromosome in each individual.
The DR7-DQ2 haplotype was seen more frequently 
among the HPA-1a–immunized women (11.7%) compared to 
the general population (5.4%; P =  .03) (Figure S2A). This 
suggests that there is a weak association of the DR7-DQ2 
haplotype in DRB3*01:01–positive HPA-1a–immunized 
women. However, there were too few individuals included 
in the study to conclude upon a potential dose effect of DQ2 
on immunization. Also, DR15-DQ6 is underrepresented in 
HPA-1a–immunized women (P = .01) (Figure S2B).
To also determine whether the DRB4*01:01 allele is as-
sociated with HPA-1a alloimmunization, we examined its 
presence in DRB3*01:01–positive immunized women and 
T A B L E  3  Frequencies of the two most common DRB3*01:01–associated DR- DQ haplotypes in HPA 1a–alloimmunized women and in the 






DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR3-DQ2) 80.9 (127) 66.7 (142) P < .003
DRB1*13:01-DQA1*01:03-DQB1*06:03 (DR13-DQ6) 20.4 (32) 32.9 (70) P < .008
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random blood donors. When comparing these two groups, 
the frequency of DRB4*01:01 is higher in immunized 
women, 9.2% (Table  S5), than in the random population 
(2.9%; P =  .01). DRB4*01 is known to be associated with 
DRB1*04, DRB1*07 and DRB1*09.29
All individuals carrying the DRB4*01:01 allele, both in 
the group of immunized women and in the general popula-
tion, also carried either the DR7-DQ2 (all DRB4*01:01–pos-
itive individuals except one) or the DR7-DQ3 haplotype (one 
immunized individual) (data not shown).
3.5 | An inflammation-associated single 
nucleotide polymorphism occurs at a higher 
frequency in alloimmunized compared 
to general population DR3-DQ2–positive 
individuals
Since DR3-DQ2 was found to be more associated with 
HPA-1a immunization, we wanted to examine whether this 
haplotype is associated with known factors that may increase 
the chance of immunization. Therefore, most individuals 
with a detected DR3-DQ2 haplotype were also typed for the 
Conserved Extended Haplotype (CEH) markers TNF-308A/ 
LTA252G/ AGER-429C by in-house allele discrimination as-
says (117 immunized women and 145 random donors were 
tested). Ninety per cent and 86% carried these markers, 
among immunized women and general population, respec-
tively (data not shown). In addition, we observed that 29.4% 
of the immunized women with the DR3-DQ2 haplotype in 
the retrospective group were homozygous for the TNF-308A 
marker, a more frequent occurrence compared to both the 
prospective group (10.9%; P < .025) and the control group 
(7.0%; P < .0008).
4 |  DISCUSSION
The association of HLA-DRB3*01:01 with HPA-1a alloim-
munization is well documented. In the present study, we 
show that also DR-DQ haplotype association significantly 
influences the prevalence of HPA-1a alloimmunization; 
women carrying DR3-DQ2 are estimated to be about twice 
as likely to become HPA-1a alloimmunized compared to 
those carrying DR13-DQ6, even though both of these hap-
lotypes are associated with the DRB3*01:01 allele. One 
third of HPA-1a–negative, DRB3*01:01–positive pregnant 
women with an HPA-1a–positive child were immunized; the 
estimated prevalence is, however, 44.5% if the DRB3*01:01 
allele is linked to the DR3-DQ2 haplotype.
The frequency of different HLA-DR-DQ haplotypes 
in the Norwegian population is known from typing by the 
Norwegian Bone Marrow Registry.15,17,19 We have focused 
on the most common haplotypes. The DRB3*01:01 allele 
is associated with several of these HLA-DR-DQ haplo-
types,15,29,31,32 and DR3-DQ2 and DR13-DQ6 represent the 
major two of these.29 The increased risk of alloimmuniza-
tion with DR3-DQ2 suggests that other genetic elements that 
F I G U R E  3  HLA-DR-DQ haplotype association with HPA-1a alloimmunization. (A) Alleles and SNPs that were specifically examined in 
this study in relation to HPA-1a alloimmunization. Those positively associated with HPA-1a alloimmunization are marked in green. (B) Haplotypes 
and SNPs positively associated with HPA-1a alloimmunization in HPA-1a–negative DRB3*01:01–positive women. C. Prevalence of HPA-1a 
alloimmunization in HPA-1a–negative women carrying DRB3*01:01 with DR3-DQ2 or with DR13-DQ6
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somehow increase the chance of HPA-1a alloimmunization 
are associated with this haplotype.
In addition to DRB3*01:01, the DQB1*02 alleles are 
also strongly associated with HPA-1a alloimmuniza-
tion.13,30 As shown herein, this association can largely be 
accounted for by its genetic linkage to the DR3-DQ2 haplo-
type; in the present study, 80.9% of DRB3*01:01–positive 
women carried the DR3-DQ2 haplotype. This linkage was 
even stronger (85.4%) when only retrospective cases were 
considered, which is similar to that analysed in a previ-
ous study.13 Therefore, the reported DQ2 association with 
alloimmunization may be coincidental. Alternatively, it is 
possible that DQB1*02 may represent a genetic element 
in the DR3-DQ2 haplotype that contributes to increased 
risk of alloimmunization with HPA-1a. In support of the 
latter, DQ2 is associated with alloimmunization also by a 
second allele not linked to DR3-DQ2. This second allele, 
DQB1*02:02, is present in the DR7-DQ2 haplotype,33 
which is the only other DR-DQ haplotype including DQ2 
besides DR3-DQ2.15
The DQB1*02:02 allele and, thus, the DR7-DQ2 hap-
lotype are present at a higher frequency in HPA-1a–allo-
immunized DRB3*01:01–positive women compared to in 
DRB3*01:01–positive individuals in the general population. 
Unlike the DRB3*01:01 allele, which has been functionally 
associated with alloimmunization, there is no evidence for a 
similar function associated with DQ2 alleles. Still, the pos-
sibility that such cells exist in HPA-1a–immunized women 
cannot be ruled out.
Taken together, there is still no direct evidence for a 
functional role of DQB1*02 in HPA-1a alloimmunization. 
Whether it is coincidental that both haplotypes found to be 
associated with HPA-1a immunization and FNAIT contain a 
DQB1*02 allele remains to be determined.
The DRB4*01:01 allele was also suggested by Loewenthal 
et al14 to be important for HPA-1a immunization, by acting 
in synergy with the DRB3*01:01 allele to cause more seri-
ous immunization in women positive for both these alleles.14 
The opposite was found, however, by L’abbé et al,13 where 
DRB4*01 seemed to be more frequent in random donors 
than in immunized women. Wienzek-Lischka et al,34 Delbos 
et al 35 and Sainio et al36 subsequently examined the role of 
this allele and did not find it to be overrepresented in HPA-1a–
immunized women. Wienzek-Lischka et al also found that 
the combination of DRB3*01:01 and DRB4*01:01/03 did 
not enhance immunization compared to only carrying the 
DRB3*01:01 allele alone.34 Although earlier reports14,30,34 
did not distinguish between DRB4*01:01 and DRB4*01:03, 
because there is no difference in exon 2 of these alleles and 
they phenotypically are the same, we chose to only focus 
on DRB4*01:01. We were more curious about the different 
DRB1 allele associations of DRB4*01:01 than the potential 
function of the molecule it codes for.
In this study, the DRB4*01:01 allele was relatively rare, 
but more frequent in already DRB3*01:01–positive immu-
nized women compared to the general population. For all 
women, except one, carrying this allele, it was associated 
with the DR7-DQ2 haplotype. Taken together, this points 
to a role for the DR7-DQ2 haplotype, and thereby may be 
for DQB1*02:02, rather than for the DRB4*01:01 allele, in 
HPA-1a immunization.
A major question addressed in this study is whether par-
ticular DR-DQ haplotypes are associated with increased 
prevalence of HPA-1a alloimmunization. This was deter-
mined by using prospective data from the Norwegian FNAIT 
screening study 4 and DR-DQ haplotype frequencies deter-
mined for the control population (random Norwegian blood 
donors that have the DRB3*01:01 allele) in the current 
study. The measured allele frequency of DRB3*01:01 in the 
Norwegian population in the current study was 14.3% (781 
random donors with a total of 1562 alleles, 224 positively 
typed DRB3*01:01 alleles), close to the allele frequency 
(14.9%) measured in a large European Caucasian population 
in the United States,29 lending support to the validity of our 
control population. We show that the prevalence of HPA-1a 
alloimmunization in the group of DRB3*01:01–positive 
women carrying DR3-DQ2 is twice as high as for women 
carrying the DR13-DQ6 haplotype. In support of these find-
ings, both Sainio et al36 and Wienzek-Lischka et al34 found 
that both DR3-DRB3*01:01 and DR13-DRB3*01:01 are 
overrepresented in immunized women compared to controls 
and that DR3-DRB3*01:01 is found more often than DR13-
DRB3*01:01. Both these studies are based on retrospective 
data, showing a DRB3*01:01 frequency of 100% and 98%, 
respectively. Benefiting from prospective data, however, 
we show a lower frequency of this allele. Most important, 
by comparing already DRB3*01:01–positive individuals we 
show here that DRB1*13:01 is overrepresented only by asso-
ciation with DRB3*01:01 and that the prevalence of immuni-
zation in the group of DRB3*01:01–positive women carrying 
DR13-DQ6 actually is lower than the prevalence of immuni-
zation in other DRB3*01:01–positive women.
The DR3-DQ2 haplotype has been studied for years, due to 
its association with a number of immune-mediated diseases, 
and especially autoimmune disorders.37-40 In Caucasians, the 
DR3-DQ2 haplotype is commonly a part of the conserved 
extended haplotype AH 8.1, (HLA-A1 - B8 - DRB3*01:01 - 
DRB1*03:01 - DQB1*02:01). In addition to the antigen-pre-
senting role of the separate HLA class II variants encoded 
within the haplotype, the non-MHC coding alleles embedded 
have also been studied, with C4A, TNF, LTA and AGER as 
candidate markers.39,41 There are several reports of constitu-
tively higher systemic levels of TNFα in healthy individuals 
with AH 8.1; however, evidence for direct influence of the 
8.1 AH marker (TNF-308A) on TNFα levels is ambiguous.42 
Our finding that almost all DR3-DQ2–positive women also 
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carry this 8.1 AH marker and that the frequency of homo-
zygous TNF-308A is higher in immunized women suggests 
that it may contribute to increase the likelihood of HPA-1a 
immunization.
Associations between HLA alleles and diseases have been 
known for about 50 years. DRB3*01:01 has also been shown 
to be associated with several diseases, in addition to HPA-1a 
immunization; for example, DRB3*01:01 is increased in pa-
tients with Grave's disease in Jamaicans43 and has been asso-
ciated with sarcoidosis.44 Whether the association between 
DRB3*01:01 and several different autoimmune diseases is 
coincidental because of the close linkage to other alleles in 
the AH8.1 haplotype is, however, uncertain. In addition to 
this, other HLA alleles and haplotypes have also been asso-
ciated with different diseases. One such well-known associ-
ation is the linkage between DQB1*02 and celiac disease, 
where the disease also is shown to be more frequent with a 
double dose of DQB1*02.45
In contrast to the positively associated alleles, the 
DRB1*15:01 allele has previously been reported as nega-
tively associated with FNAIT, suggesting a regulatory or sup-
pressive role of this allele.30 This negative association was 
also found in the current study, although we here suggest that 
the negative association can be accounted for by the presence 
of this allele in an underrepresented haplotype: DR15-DQ6. 
It is possible that the negative association with FNAIT could 
be due to other elements present in this haplotype and not 
necessarily the DRB1*15:01 allele itself.
As the methods for HLA typing that were applied were 
published some years ago and do not reflect the current stan-
dard of HLA typing, it cannot completely be ruled out that 
new HLA alleles could have been amplified by the primers 
used for HLA typing. Alignments of all DRB3 alleles known 
to this date, with primers in the current study for detection 
of DRB3*01:01, show that the primer pairs would also have 
amplified, among others, DRB3*02:06, *02:08, *02:21, 
*02:44, and *02:56. Common for all these alleles, how-
ever, is that they have only been found once by one lab and 
only one of them is confirmed. In addition, the prevalence 
of these alleles in different ethnic populations is not known. 
Thus, if one or two new HLA alleles had erroneously been 
amplified, it is unlikely that this would have influenced our 
main results.
The main results of this study are summarized in Figure 3. 
In summary, this study represents one of few studies in which 
MHC allele associations with HPA-1a immunization have 
taken into consideration the strong linkage disequilibrium 
that exist between specific MHC alleles. More importantly, 
and based on data from a prospective screening study, our 
results indicate that the haplotype which is associated with 
the DRB3*01:01 allele has a considerable impact on the 
chance of HPA-1a alloimmunization, likely due to yet not 
identified associated genetic elements. The haplotypes and 
alleles identified herein point to genetic elements that will 
be investigated for greater insight into the immune response 
that results in FNAIT. Potentially, these may guide a more 
accurate identification of pregnancies most at risk of FNAIT, 
in a clinical setting.
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